Retatrutide Guide

Phase 2/3 trial dosing schedules, dose escalation protocol, and half-life stacking mechanism. The complete reference for reta dosing.

A slower dosage schedule starting at 0.5 mg/week — designed for GI-sensitive and first-time GLP-1 users. Includes dose chart and injection guidance.

The standard dosage schedule starting at 2 mg/week, matching the TRIUMPH-4 Phase 3 clinical trial. Includes dose chart and published efficacy data.

Dosage chart for twice-weekly injection — divides the weekly total across 2 doses for smoother drug levels and fewer side effects.

Phase 2 trial safety data, GI mechanism, severity by dose tier, and management strategies. What to expect and when to worry.

Why taking too much reta causes severe GI side effects, how to tell if you're over your therapeutic window, and what to do about it.

Why your dose stopped working, the adaptation cycle, signals you're underdosed, and data-driven escalation strategy. Most "plateaus" are fixable.

How the one-compartment pharmacokinetic model works, what the drug level curve means, and how Retadose estimates your current concentration.

Half-life of 144–165 hours from Coskun 2022, dose stacking math, steady-state timing, and comparison with semaglutide and tirzepatide.

Feature comparison of Retadose vs Shotsy, GLP1Plotter, and DoseDiary for retatrutide tracking. What each tool does and doesn't do.

Compounded retatrutide pricing, insurance coverage status, legal access pathways, and cost-per-month at each dosage tier.

Mechanism comparison (triple vs dual agonist), Phase 2/3 efficacy data, pharmacokinetic differences, and which one might be better for you.